Carolyn D Britten

Carolyn D Britten

UNVERIFIED PROFILE

Are you Carolyn D Britten?   Register this Author

Register author
Carolyn D Britten

Carolyn D Britten

Publications by authors named "Carolyn D Britten"

Are you Carolyn D Britten?   Register this Author

34Publications

724Reads

45Profile Views

Automatic trial eligibility surveillance based on unstructured clinical data.

Int J Med Inform 2019 Sep 23;129:13-19. Epub 2019 May 23.

Division of Hematology/Oncology, Medical University of South Carolina, Charleston, SC, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijmedinf.2019.05.018DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6717538PMC
September 2019

Comparison of Triple-Drug Transcatheter Arterial Chemoembolization (TACE) With Single-Drug TACE Using Doxorubicin-Eluting Beads: Long-Term Survival in 313 Patients.

AJR Am J Roentgenol 2017 Oct 13;209(4):722-732. Epub 2017 Jul 13.

4 Department of Medicine, Surgery, The David Geffen School of Medicine at the University of California at Los Angeles, Los Angeles, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2214/AJR.17.18219DOI Listing
October 2017

Racial Differences in Stage IV Colorectal Cancer Survival in Younger and Older Patients.

Clin Colorectal Cancer 2017 09 7;16(3):178-186. Epub 2016 Dec 7.

Hollings Cancer Center, Medical University of South Carolina, Charleston, SC; Department of Public Health Sciences, Medical University of South Carolina, Charleston, SC.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15330028163026
Publisher Site
http://dx.doi.org/10.1016/j.clcc.2016.11.006DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5462873PMC
September 2017

Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study.

J Clin Oncol 2017 Jul 4;35(19):2117-2124. Epub 2017 Apr 4.

Andrea B. Apolo and James L. Gulley, National Institutes of Health, Bethesda, MD; Jeffrey R. Infante, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Ani Balmanoukian, The Angeles Clinic & Research Institute; Alain C. Mita, Cedars Sinai Medical Center, Los Angeles; Karen Kelly, University of California-Davis, Sacramento; Marko Srdanov, Dako North America, Carpinteria, CA; Manish R. Patel, Florida Cancer Specialists & Research Institute, Sarasota, FL; Ding Wang, Henry Ford Hospital, Detroit, MI; Anthony E. Mega, The Warren Alpert Medical School at Brown University; Howard Safran, The Miriam Hospital, Providence; Howard Safran, Newport Hospital, Newport, RI; Carolyn D. Britten, Medical University of South Carolina, Charleston, SC; Alain Ravaud, CHU de Bordeaux, Bordeaux, France; Thomas E. Stinchcombe, Duke University Medical Center, Durham, NC; Arnold B. Gelb and Kevin Chin, EMD Serono, Billerica, MA; and Michael Schlichting, Merck, Darmstadt, Germany.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2016.71.6795
Publisher Site
http://dx.doi.org/10.1200/JCO.2016.71.6795DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5493051PMC
July 2017

Redox Signaling and Bioenergetics Influence Lung Cancer Cell Line Sensitivity to the Isoflavone ME-344.

J Pharmacol Exp Ther 2016 08 2;358(2):199-208. Epub 2016 Jun 2.

Departments of Cell and Molecular Pharmacology and Experimental Therapeutics (Y.M., L.R., K.T.), Medicine (C.B.), and Drug Discovery and Biomedical Sciences (D.T.) of the Medical University of South Carolina, Charleston, South Carolina

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/jpet.115.229344DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4959101PMC
August 2016

The effect of formulation and food consumption on the bioavailability of dovitinib (TKI258) in patients with advanced solid tumors.

Cancer Chemother Pharmacol 2014 Oct 6;74(4):867-74. Epub 2014 Sep 6.

Huntsman Cancer Institute, University of Utah, 2000 Circle of Hope Dr, Rm 3360, Salt Lake City, UT, 84112, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-014-2454-4DOI Listing
October 2014

PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types.

Cancer Chemother Pharmacol 2013 Jun 27;71(6):1395-409. Epub 2013 Feb 27.

Division of Hematology/Oncology, Department of Medicine, Hollings Cancer Center, Medical University of South Carolina, 96 Jonathan Lucas Street, Clinical Science Building, Suite 903, Charleston, SC 29425, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00280-013-2121-1
Publisher Site
http://dx.doi.org/10.1007/s00280-013-2121-1DOI Listing
June 2013

Transarterial chemoembolization plus or minus intravenous bevacizumab in the treatment of hepatocellular cancer: a pilot study.

BMC Cancer 2012 Jan 14;12:16. Epub 2012 Jan 14.

Division of Hematology/Oncology, Department of Medicine, David Geffen School of Medicine at the University of California, Los Angeles, Santa Monica, CA 90404-2429, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1471-2407-12-16DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3292503PMC
January 2012

Resection of thyroid cancer metastases to the sternum.

J Thorac Oncol 2009 Aug;4(8):1022-5

Lung Cancer Research Program of the Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0b013e3181adef20DOI Listing
August 2009

Targeting vascular endothelial growth factor with the monoclonal antibody bevacizumab inhibits human hepatocellular carcinoma cells growing in an orthotopic mouse model.

Liver Int 2009 Feb 14;29(2):284-90. Epub 2008 May 14.

Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine at UCLA, Los Angeles, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1478-3231.2008.01762.xDOI Listing
February 2009

Pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors: correlations with clinical characteristics and safety.

Cancer Chemother Pharmacol 2008 Jun 6;62(1):97-109. Epub 2007 Sep 6.

Department of Oncology, Pfizer Global Research and Development, 50 Pequot Avenue MS6025-A3238, New London, CT 06320, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00280-007-0579-4
Publisher Site
http://dx.doi.org/10.1007/s00280-007-0579-4DOI Listing
June 2008

A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period.

Cancer Chemother Pharmacol 2008 Mar 16;61(3):515-24. Epub 2007 May 16.

David Geffen School of Medicine at the University of California, Los Angeles 90095, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-007-0498-4DOI Listing
March 2008

First study of the safety, tolerability, and pharmacokinetics of CP-724,714 in patients with advanced malignant solid HER2-expressing tumors.

Clin Cancer Res 2007 Feb;13(4):1238-45

Department of Interdisciplinary Oncology, Experimental Therapeutics Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-06-1539DOI Listing
February 2007

Targeting ErbB receptor signaling: a pan-ErbB approach to cancer.

Mol Cancer Ther 2004 Oct;3(10):1335-42

Division of Hematology/Oncology, Department of Medicine, David Geffen School of Medicine at University of California at Los Angeles, 10945 Le Conte Avenue, Los Angeles, CA 90095, USA.

View Article

Download full-text PDF

Source
October 2004

Clinical trial designs for targeted agents.

Hematol Oncol Clin North Am 2002 Oct;16(5):1287-305

Department of Medical Oncology, Princess Margaret Hospital, University Health Network, 610 University Avenue, Toronto, ON M5G 2M9, Canada.

View Article

Download full-text PDF

Source
October 2002

A phase I study of pivaloyloxymethyl butyrate, a prodrug of the differentiating agent butyric acid, in patients with advanced solid malignancies.

Clin Cancer Res 2002 Jul;8(7):2142-8

Institute for Drug Development, Cancer Therapy and Research Center and The University of Texas Health Science Center at San Antonio, Texas 78229, USA.

View Article

Download full-text PDF

Source
July 2002